- 著者
- Liying Dong Shasha Hu Jianjun Gao
- 出版者
- International Research and Cooperation Association for Bio & Socio-Sciences Advancement
- 雑誌
- Drug Discoveries & Therapeutics (ISSN:18817831)
- 巻号頁・発行日
- vol.14, no.1, pp.58-60, 2020-02-29 (Released:2020-03-08)
- 参考文献数
- 19
- 被引用文献数
- 931
The SARS-CoV-2 virus emerged in December 2019 and then spread rapidly worldwide, particularly to China, Japan, and South Korea. Scientists are endeavoring to find antivirals specific to the virus. Several drugs such as chloroquine, arbidol, remdesivir, and favipiravir are currently undergoing clinical studies to test their efficacy and safety in the treatment of coronavirus disease 2019 (COVID-19) in China; some promising results have been achieved thus far. This article summarizes agents with potential efficacy against SARS-CoV-2.
11 0 0 0 OA Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19)
- 著者
- Jianjun Gao Shasha Hu
- 出版者
- International Research and Cooperation Association for Bio & Socio-Sciences Advancement
- 雑誌
- BioScience Trends (ISSN:18817815)
- 巻号頁・発行日
- pp.2020.03072, (Released:2020-04-13)
- 参考文献数
- 17
- 被引用文献数
- 38
Drugs that are specifically efficacious against SARS-CoV-2 have yet to be established. Chloroquine and hydroxychloroquine have garnered considerable attention for their potential to treat coronavirus disease 2019 (COVID-19). Increasing evidence obtained from completed clinical studies indicates the prospects for chloroquine/hydroxychloroquine to treat COVID-19. More randomized control clinical studies are warranted to determine the feasibility of these two drugs in treating COVID-19.
3 0 0 0 OA Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19)
- 著者
- Jianjun Gao Shasha Hu
- 出版者
- International Research and Cooperation Association for Bio & Socio-Sciences Advancement
- 雑誌
- BioScience Trends (ISSN:18817815)
- 巻号頁・発行日
- vol.14, no.2, pp.156-158, 2020-04-30 (Released:2020-05-21)
- 参考文献数
- 17
- 被引用文献数
- 15 38
Drugs that are specifically efficacious against SARS-CoV-2 have yet to be established. Chloroquine and hydroxychloroquine have garnered considerable attention for their potential to treat coronavirus disease 2019 (COVID-19). Increasing evidence obtained from completed clinical studies indicates the prospects for chloroquine/hydroxychloroquine to treat COVID-19. More randomized control clinical studies are warranted to determine the feasibility of these two drugs in treating COVID-19.